Ferring and Foresee Pharmaceuticals enter into exclusive development and option agreement.
Ferring Pharmaceuticals and Foresee Pharmaceuticals Co., Ltd. announced that the companies have entered into an exclusive worldwide development and option agreement to leverage Foresee’s proprietary Stabilized Injectable Formulation platform (SIF) for the development of long duration, controlled release formulations of a peptide therapeutic.
Under the terms of the agreement, Ferring will fund the development work and, upon completion, Ferring will have the right to exercise its option and enter into a definitive agreement with Foresee. Execution of a definitive agreement would entitle Foresee to additional payments including upfront, milestones and royalties based on net sales of the product(s) commercialized by Ferring.
“We have been impressed with Foresee’s achievements to date and we see value in its SIF platform technology,” said Alan S. Harris, senior vice president, R&D executive office at Ferring. “The technical barriers Foresee has overcome in developing stable, formulated peptides in solution for controlled release therapy for three and six-month durations of action after a single injection are quite significant, and this gives us much confidence in the potential of the SIF platform applied to complex peptide drug substances. We are enthusiastic about this new collaboration.”
Dr. Ben Chien, chairman and CEO of Foresee, said, “We are excited about entering into this collaboration with Ferring, a global specialty pharmaceutical company with a long-standing history of innovation in the area of injectable therapeutic peptides and the application of novel formulations and delivery technologies to generate differentiated product profiles. We are confident that our SIF platform will provide significant value to Ferring’s R&D product portfolio and very much look forward to working with them on this project.”
(Source: Business Wire)
Filed Under: Drug Discovery